All News
ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis
EurekAlert!
The American College of Physicians (ACP) has issued an update of its guideline with clinical recommendations for treatments of primary osteoporosis and low bone mass in adults.
Read Article
2022 Match - Strong Appeal of Adult Rheumatology, Less So in Pediatric Rheumatology
ACR
The American College of Rheumatology is pleased to announce another successful recruitment season and welcomes this impressive pool of applicants to the field of rheumatology.
Read Article
Extreme Global Costs of Physical Inactivity
A global, population-based study shows that physical inactivity is not only an important modifiable risk factor for non-communicable diseases (NCDs) and mental health conditions, it also imparts a considerable health and economic burden that is avoidable.
Read Article
608 EARLY RA pts in BARFOT study had Xrays over time. 24% did not show Erosions after 8 yrs. Pt w/ NO Erosions were younger, younger, w Less ACR criteria, & seronegative at Dx. They had more TJC, less SJC, lower ESR, less DMARDs & pred Rx. https://t.co/5jYNd7bwE3 https://t.co/z3Y0TPJTwd
Links:
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGISTS: have you ever ordered a Fibroscan in patients taking Methotrexate?
Dr. John Cush RheumNow ( View Tweet)
Nifty little read about dx and tx algorithms in monogenic autoinflammatory disease
I think we need to start generating more diagnostic algorithms and "approach to" articles
Working on a series for my fellows and have had a hard time finding material! https://t.co/DYmgSyjILi
Mike Putman EBRheum ( View Tweet)
There is considerable overlap between fibromyalgia tender points and an enthesitis score in axial spondyloarthritis pts. 526 pts in the Predict-SpA study (53% men, 38% FM) assessed 18 TP and 13 Entheses found ICC between both scores of 0.7 https://t.co/ESmP26plDB https://t.co/7X1XhyML0f
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of 2022: Allopurinol Safety in CKD Patients
https://t.co/BDjuL2Fp94 https://t.co/d3Jo4SKwHQ
Links:
Dr. John Cush RheumNow ( View Tweet)
FDG-PET Scan in RA? Study of 34 #RA pts shows PET uptake (SUV scores) measures were significantly correlated with the number of swollen joints, SDAID but not the CDAI, disease duration, seropositivity, or RA treatments. https://t.co/AkGhEiNqwt https://t.co/FkKh49KYyd
Links:
Dr. John Cush RheumNow ( View Tweet)
10% of PsA is PsA Sine Psoriasis - how to differentiate from seroneg RA? PsA sine PsO pts have peripheral arthritis, no skin dz, but may have axial sxs, +Family Hx or nail psoriasis, dactylitis, enthesitis, DIP involvement. https://t.co/BeYOq8ysgW https://t.co/pLogz1HHTV
Links:
Dr. John Cush RheumNow ( View Tweet)
IL-18 is a proinflammatory cytokine involved in innate & adaptive immune responses. IL-18 is a key mediator in autoinflammatory diseases, MAS, Still’s disease. Serum IL-18 levels may be useful in diagnosis and monitoring of disease activity https://t.co/1SXlODZcXc https://t.co/xtauaMMMos
Links:
Dr. John Cush RheumNow ( View Tweet)
Does Methotrexate Use Lead to Melanoma?
A systematic review suggests that low-dose methotrexate (MTX) use is associated with an increased melanoma risk, but the absolute risk increase could be considered negligible.
https://t.co/dChsIsCAMt https://t.co/5PgjlunTmp
Links:
Dr. John Cush RheumNow ( View Tweet)
Drugs causing Scleroderma (DASSc) - Anticancer rx made up 42% DASSc & 62.3% case reports. Included: taxane-based agents, bleomycin, vinblastine, imatinib, dacarbazine, pembrolizumab pemetrexed; also HRT romiplostim & eculizumab https://t.co/jPNIuaYdnJ https://t.co/efZG5kG2Yd
Links:
Dr. John Cush RheumNow ( View Tweet)
2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/zjxZtTFnlS https://t.co/XTwip2wv1n
Links:
Dr. John Cush RheumNow ( View Tweet)
Rituximab Efficacy in Systemic Sclerosis
The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase.
https://t.co/cqlVo104Y9 https://t.co/dYgBsj65BJ
Links:
Dr. John Cush RheumNow ( View Tweet)
AVOID THE WEEKEND! Study of high-impact rheumatology journals (Rheumatology, J Rheum, & Seminars A&R) shows higher risk of "desk rejections" by editor (avoiding peer review) for manuscripts submitted Saturday (OR 1.23) or Sunday (OR 1.13) https://t.co/rWIkiYgh8Y https://t.co/kPSJmfWSUl
Links:
Dr. John Cush RheumNow ( View Tweet)
Treatment of pyoderma gangrenosum is clinically empiric. Full read ref w/ Graded Rx Recommendations:
- 1st line: Steriods or Cyclosporin
- Consider biologics: TNFi, IL-1, IL-12/23, IL-17, IL-23
- Others: MTX, MMF, AZA, Dap, colchic, thalidomide, IVIG
https://t.co/z0XeT0ja45 https://t.co/fWAcryIDJR
Links:
Dr. John Cush RheumNow ( View Tweet)
Women Heroes in Rheum:
- Barbara Ansell - JIA
- Nanna Svartz - SSZ
- Gertrude Elion - Nobel Prize for allopurinol, AZA
- Tsai-Fan Yu - gout Rx
- Mary Betty Stevens - lupus & vasculitis
- Marian Ropes - 1st F ARA president
- Fionula Brennan - TNFi
& more
https://t.co/FDRORJ7c1q https://t.co/ZebVagIyQA
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of 2022: Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines
https://t.co/Swf5kq6VtG https://t.co/UTIaCFpAX6
Links:
Dr. John Cush RheumNow ( View Tweet)
Good review of Diagnosis and Treatment of Pulmonary Sarcoidosis in JAMA.
- Lung progression (in only 10%) assoc w/ 12-18% 5yr mortality
- Sx Sarcoid w/ Lung: start Pred 20 to 40 mg/d for 2 -6 wks
- Steroid sparing w/ MTX, AZA or TNFi
https://t.co/aVnUXaj0sj https://t.co/JN142hlR6g
Links:
Dr. John Cush RheumNow ( View Tweet)
